Health Care Sector

Raydel Australia and Cuba’s CNIC Sign Joint Venture

Raydel Australia PTY LTD and the National Center for Scientific Research (CNIC) have established a joint venture to commercialize the use of Policosanol (PPG) and Abexol medicines.

The joint venture expands the international presence of the Biotechnological and Pharmaceutical Industries Group (BioCubaFarma), enhancing the international prestige of the island’s biopharmaceutical sector.

Dr. Kyung-Hyun Cho, head of RAYDEL Research Institute and Dr. Yoshinari Uehara, M.D. Ph.D., of the Department of Cardiology, Fukuoka University Hospital took part in the event at the Cuban Embassy in Australia.

The Raydel Group Australia

The Raydel Group has branch offices in Korea, Japan and China. It is a pharmaceutical manufacturing company offering high quality, naturally-sourced products that enhance life quality and provide health benefits to patients.

Advertisement. Scroll to continue reading.

CNIC is a part of the BioCubaFarma Group

Founded in 1965, the CNIC is a part of the BioCubaFarma business group. The company is dedicated to research, production and pharmaceutical marketing. The CNIC is the first multidisciplinary scientific center in Cuba.

The CNIC and Raydel’s joint venture endorses a long tradition of collaboration in Cuban biopharmaceuticals. It also promotes the reputation and usage of the two drugs in the international marketplace.

Julio Alfonso, president of Dalmer Laboratories S.A., for the CNIC, and Byong Ku Lee, general director of Raydel, signed the agreement. The joint venture confirms the will of both companies to continue developing the strategic alliance.

Clinical trials in Cuba confirmed the effectiveness of PPG as a potential adjuvant drug to control pre-hypertension and hypertension in patients with low cardiovascular risk. The results showed a significant decrease in maximum and minimum values after 12 weeks of testing.

Advertisement. Scroll to continue reading.

Abexol is used for the relief of mild osteoarthritis, enhances healthy joint function and mobility and maintains gastrointestinal health.

The results of the clinical trial favor usage for other pathologies and will increase its presence in the international marketplace.

The derivation of PPG and Abexol from sugar cane wax minimizes adverse side effects.

Advertisement. Scroll to continue reading.

Recent Posts

Cuba Joins the BRICS New Development Bank

In a move with both economic and geopolitical significance, Cuba has officially joined the New…

1 week ago

Cuba’s International Tourist Arrivals—June 2025

Cuba’s tourism sector, long a vital part of the island’s economy, is experiencing mixed fortunes…

2 weeks ago

Cuba Amplifies Voice of the Global South at BRICS 2025 in Brazil

Cuba took center stage at the 17th BRICS 2025 in Rio de Janeiro this weekend,…

1 month ago

FIHAV 2025 Set for this November

Cuba has confirmed the 41st edition of the Havana International Fair (FIHAV 2025) will take…

1 month ago

WestJet CEO Meets with Cuban President Amid Hopes for Expansion of Passenger Flights to Havana

WestJet CEO Alexis von Hoensbroech met Wednesday with Cuban President Miguel Díaz-Canel in Havana, a high-level meeting…

2 months ago

Cuba Expands Solar Parks as Energy Deficits Persist

Cuba is ramping up efforts to address energy shortages through the expansion of photovoltaic solar…

2 months ago